Your next you is your best you
For a detailed comparison between tirzepatide and its closest competitor, the semaglutide vs tirzepatide comparison page covers mechanisms, efficacy, side effect profiles, and dosing differences
It also decreased hepatic expression of CD36 and odorant-binding protein 2A, both involved in lipid uptake
The SYNERGY-NASH trial, published in the New England Journal of Medicine in June 2024, provides the strongest evidence we have for tirzepatide (the drug in Mounjaro) in fatty liver disease
External resources For researchers serious about optimizing their tirzepatide protocols, SeekPeptides offers the most comprehensive resource available, with evidence-based guides, proven protocols, and a community of thousands who have navigated these exact questions